One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ewing sarcoma is characterized by the EWS/FLI oncogene, a driver of malignant transformation.
• The tumor's dependence on EWS/FLI highlights its critical role in maintaining the malignant phenotype.
• EWS/FLI functions as a transcription factor, posing significant challenges for direct drug targeting.

Purpose of the Study:

• To review therapeutic strategies targeting the EWS/FLI transcriptional network in Ewing sarcoma.
• To explore opportunities arising from the complex protein interactions within this network.
• To summarize advancements in identifying compounds targeting EWS/FLI and its vulnerabilities over the past two decades.

Main Methods:

• Review of scientific literature on EWS/FLI in Ewing sarcoma.
• Analysis of the EWS/FLI transcriptional network, including interacting proteins and effectors.
• Identification of therapeutic compounds targeting EWS/FLI and associated vulnerabilities.

Main Results:

• EWS/FLI drives Ewing sarcoma through a complex transcriptional network.
• Directly targeting EWS/FLI is difficult due to its nature as a transcription factor.
• The network's complexity offers multiple therapeutic intervention points.

Conclusions:

• The EWS/FLI transcriptional network presents both challenges and opportunities for Ewing sarcoma therapy.
• Exploiting vulnerabilities within this network has led to the identification of potential therapeutic compounds.
• Continued research into the EWS/FLI network is crucial for developing effective treatments.